Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAMARK first-line BRAF V600E MSI-H/dMMR metastatic colorectal cancer study
2024-512119-34-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) comparing Encorafenib + cetuximab + pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoint: Progression-free survival. Planned start Jun 2022; status: authorised.
02
Drugs
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2024-512119-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512119-34-00.